✦ LIBER ✦

Phase-3 randomized trial of everolimus (RAD001) vs. placebo in advanced pancreatic NET (RADIANT-3)

✍ Scribed by Jonathan Chambers; Nick Reed; Was Mansoor; Paul Ross; Ashley Grossman

Book ID: 113873663
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 83 KB
Volume: 164
Category: Article
ISSN: 0167-0115
DOI: 10.1016/j.regpep.2010.07.018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

257 UPDATED DATA FROM A PHASE 3 TRIAL OF

257 UPDATED DATA FROM A PHASE 3 TRIAL OF EVEROLIMUS (RAD001) VERSUS PLACEBO IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

✍ A. Kay; R.J. Motzer; R.A. Figlin; B. Escudier; S. Oudard; C. Porta; T.E. Hutson; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 517 KB

6561 POSTER Updated Survival and Safety

6561 POSTER Updated Survival and Safety Data From RADIANT-3 – a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Trial of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumours (pNET)

✍ Lombard-Bohas, C.; Van Cutsem, E.; Capdevila, J.; de Vries, E.G.E.; Tomassetti, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

6566 POSTER Updated Safety and Efficacy

6566 POSTER Updated Safety and Efficacy Results From RADIANT-2 – a Randomized, Double-blind, Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Pts With Advanced Neuroendocrine Tumours (NET)

✍ Ricci, S.; Ruszniewski, P.; Tomasetti, P.; Jehl, V.; Saletan, S.; Yao, J.C.; Pav 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB

6573 POSTER Effect of Everolimus Treatme

6573 POSTER Effect of Everolimus Treatment on Markers of Angiogenesis in Patients With Advanced Pancreatic Neuroendocrine Tumours (pNET) – Results From the Phase III RADIANT-3 Study

✍ Yao, J.C.; Tsuchihashi, Z.; Panneerselvam, A.; Winkler, R.E.; Bugarini, R.; Pave 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

6571 POSTER Impact of Prior Somatostatin

6571 POSTER Impact of Prior Somatostatin Analog (SSA) Use on PFS in the Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Patients With Advanced Neuroendocrine Tumours (RADIANT-2)

✍ Pavel, M.; Singh, N.; Passos, V.; Oberg, K. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Integrated data from 2 randomized, doubl

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

✍ Celestia S. Higano; Paul F. Schellhammer; Eric J. Small; Patrick A. Burch; John 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 402 KB

## Abstract ## BACKGROUND: Sipuleucel‐T is an investigational active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. The safety and efficacy of sipuleucel‐T was evaluated in 2 identically designed, randomized, double‐blind, placebo‐controlled trials